Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.89), in-line with the analyst estimate of ($0.89). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.43 million.

“Starting in January with the field launch, Gvoke PFS began to see a very positive response from the diabetes community as evidenced by early and steady uptake of prescriptions, units, and units per prescription until the dynamics of the ongoing COVID-19 pandemic slowed our momentum. In response to the pandemic, we quickly moved to a virtual selling model and implemented several programs in an effort to minimize the impact of the crisis on the diabetes patient community and our business,” said Paul R. Edick, Chairman and CEO of Xeris. “The second quarter will be extremely busy as we work to drive Gvoke PFS prescription growth, prepare for the July launch of Gvoke HypoPen, and report topline results from three additional clinical programs.”

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.